EG-70 (phase 1)

PreclinicalProtein / enzyme

EG-70 (phase 1) is one of 2 small molecule programs targeting Superficial Bladder Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Superficial Bladder CancerRecruiting

Superficial Bladder CancerPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Superficial Bladder Cancer

#DrugCompanyPhaseTrials

Abnobaviscum 900

EG-70 (phase 1)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Superficial Bladder Cancer

NCT04752722

Clinical

Trials by Indication[1]

Superficial Bladder Cancer1 trial

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

Recruiting·EenGene, Inc.·Preclinical·NCT04752722·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EG-70 (phase 1). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EG-70 (phase 1) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EG-70 (phase 1). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — enGene, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: EenGene, Inc.

EG-70 (phase 1)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Superficial Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News